Research programme: recombinant Midkine protein - Cellmid

Drug Profile

Research programme: recombinant Midkine protein - Cellmid

Alternative Names: CMK 103

Latest Information Update: 13 Jul 2016

Price : $50

At a glance

  • Originator Cellmid
  • Class Recombinant proteins
  • Mechanism of Action Apoptosis inhibitors; MDK protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Myocardial infarction

Most Recent Events

  • 13 Jul 2016 Preclinical development is ongoing in Australia with Cellmid and its subsidiary Kinera
  • 02 Feb 2010 Preclinical trials in Myocardial infarction in Australia (unspecified route)
  • 02 Feb 2010 Preclinical trials in Cerebral ischaemia in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top